Mackenzie Financial
SGMO

Mackenzie Financial’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Mackenzie Financial’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-43,920
Closed -$29.4K – 1617
2024
Q1 		$29.4K Sell
43,920
-29,879
-40% -$21.7K ﹤0.01% 1500
2023
Q4 		$40.1K Buy
73,799
+31,003
+72% +$14.3K ﹤0.01% 1457
2023
Q3 		$24.5K Buy
42,796
+12,228
+40% +$13.1K ﹤0.01% 1447
2023
Q2 		$41.3K Buy
+30,568
New +$41.8K ﹤0.01% 1470
2022
Q4 		– Sell
-90,638
Closed -$444K – 1567
2022
Q3 		$444K Buy
+90,638
New +$466K ﹤0.01% 968
2021
Q1 		– Sell
-18,000
Closed -$281K – 1189
2020
Q4 		$281K Sell
18,000
-65,500
-78% -$767K ﹤0.01% 952
2020
Q3 		$789K Buy
+83,500
New +$903K ﹤0.01% 718

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Mackenzie Financial's SGMO Position: Q2 2024 in Review

Mackenzie Financial sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2024, closing a stake of 43,920 shares — an estimated $29.4K sold.

Mackenzie Financial first reported a position in SGMO in Q3 2020 and held it in 7 quarters. The position peaked at $789K in Q3 2020. 129 funds tracked by Wall St. Rank hold SGMO as of Q2 2024.

  • Mackenzie Financial reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2024 after selling out during the quarter.
  • Mackenzie Financial sold 43,920 SANGAMO THERAPEUTICS INC shares in Q2 2024, an estimated $29.4K.
  • Mackenzie Financial first reported a position in SANGAMO THERAPEUTICS INC in Q3 2020 and held it in 7 quarters.
  • Mackenzie Financial's SANGAMO THERAPEUTICS INC position peaked at $789K in Q3 2020.
  • 129 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2024.

Based on Mackenzie Financial's 13F filing for Q2 2024, filed 14 Aug 2024.